2026年8月31日•1分で読めます
Samsung Bioepis, Proteina Expand AI Antibody Development
Samsung Bioepis and Proteina signed a license option agreement to advance AI‑driven antibody drug discovery from candidate identification to commercialization, building on a government AI project.